Phenotype of Human CD45+ Cells in the Bone Marrow of Mice Injected With CD34+/Lin− or CD34+/CD38−Cells
| Treatment (no. of mice) . | Proportion of CD45+ Human Cells (range) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocytes . | Myelocytes . | CD19 . | CD20 . | IgM . | CD33 . | CD13 . | CD14 . | CD15 . | CD34 . | |
| CD34+/CD38− | ||||||||||
| NoGF | 45 | 34 | 53 | 31 | 9 | 44 | 30 | 7 | 10 | 13 |
| (2) | (32-57) | (26-42) | (46-60) | (29-33) | (7-10) | (31-56) | (19-41) | (6-8) | (7-12) | (4-21) |
| SCF/GM-CSF/IL-3 | 44 | 39 | 53 | 32 | 8 | 42 | 30 | 8 | 11 | 13 |
| (5) | (25-58) | (27-63) | (34-62) | (17-40) | (6-10) | (28-68) | (13-58) | (4-10) | (6-16) | (8-15) |
| FL/SCF/IL-3 | 14 | 66 | 17 | 11 | 4 | 72 | 50 | 14 | 13 | 10 |
| (3) | (4-23) | (63-68) | (12-23) | (8-16) | (0-7) | (63-90) | (31-73) | (10-17) | (8-17) | (5-17) |
| CD34+/Lin− | ||||||||||
| NoGF | 63 | 26 | 69 | 60 | 30 | 26 | 15 | 8 | 7 | 2 |
| (1) | ||||||||||
| FL/IL-7 | 15 | 77 | 10 | 7 | 4 | 84 | 51 | 21 | 27 | 8 |
| (2) | (4-26) | (63-93) | (4-15) | (1-12) | (0-8) | (77-90) | (41-60) | (18-24) | (21-32) | (6-9) |
| Treatment (no. of mice) . | Proportion of CD45+ Human Cells (range) . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lymphocytes . | Myelocytes . | CD19 . | CD20 . | IgM . | CD33 . | CD13 . | CD14 . | CD15 . | CD34 . | |
| CD34+/CD38− | ||||||||||
| NoGF | 45 | 34 | 53 | 31 | 9 | 44 | 30 | 7 | 10 | 13 |
| (2) | (32-57) | (26-42) | (46-60) | (29-33) | (7-10) | (31-56) | (19-41) | (6-8) | (7-12) | (4-21) |
| SCF/GM-CSF/IL-3 | 44 | 39 | 53 | 32 | 8 | 42 | 30 | 8 | 11 | 13 |
| (5) | (25-58) | (27-63) | (34-62) | (17-40) | (6-10) | (28-68) | (13-58) | (4-10) | (6-16) | (8-15) |
| FL/SCF/IL-3 | 14 | 66 | 17 | 11 | 4 | 72 | 50 | 14 | 13 | 10 |
| (3) | (4-23) | (63-68) | (12-23) | (8-16) | (0-7) | (63-90) | (31-73) | (10-17) | (8-17) | (5-17) |
| CD34+/Lin− | ||||||||||
| NoGF | 63 | 26 | 69 | 60 | 30 | 26 | 15 | 8 | 7 | 2 |
| (1) | ||||||||||
| FL/IL-7 | 15 | 77 | 10 | 7 | 4 | 84 | 51 | 21 | 27 | 8 |
| (2) | (4-26) | (63-93) | (4-15) | (1-12) | (0-8) | (77-90) | (41-60) | (18-24) | (21-32) | (6-9) |
The proportion of CD45+ human cells coexpressing the indicated cell-surface phenotype is given as the average (and range) from the indicated number of mice. The lymphocyte and myelocyte percentages were calculated as described in Fig 3.